150 related articles for article (PubMed ID: 15188002)
21. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
22. Enhanced elimination of Ph+ chromosome cells in vitro by combined hyperthermia and other drugs (AZT, IFN-alpha, TNF, and quercetin): its application to autologous bone marrow transplantation for CML.
Osman Y; Moriyama Y; Shibata A
Exp Hematol; 1995 May; 23(5):444-52. PubMed ID: 7720816
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G
Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433
[TBL] [Abstract][Full Text] [Related]
24. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
25. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
26. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
[TBL] [Abstract][Full Text] [Related]
27. Interferon gamma is effective for BM purging in a patient with CML.
Becker M; Fabrega S; Belloc F; Rice A; Barbu V; Reiffers J
Bone Marrow Transplant; 1993 Aug; 12(2):155-8. PubMed ID: 8401363
[TBL] [Abstract][Full Text] [Related]
28. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
29. BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
Schultheis B; Pasternak G; Hehlmann R
Folia Biol (Praha); 2000; 46(6):256-63. PubMed ID: 11140859
[TBL] [Abstract][Full Text] [Related]
30. Long-term culture of autologous bone marrow for marrow reconstitution following high-dose chemotherapy. Purging with tumor surface antigen directed human-human monoclonal antibody.
Alonso K; Medenica R; Morehead G
Prog Clin Biol Res; 1994; 389():111-8. PubMed ID: 7700892
[No Abstract] [Full Text] [Related]
31. Protein kinase A-independent inhibition of proliferation and induction of apoptosis in human thyroid cancer cells by 8-Cl-adenosine.
Robinson-White AJ; Hsiao HP; Leitner WW; Greene E; Bauer A; Krett NL; Nesterova M; Stratakis CA
J Clin Endocrinol Metab; 2008 Mar; 93(3):1020-9. PubMed ID: 18073299
[TBL] [Abstract][Full Text] [Related]
32. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
[TBL] [Abstract][Full Text] [Related]
33. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
34. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
35. Combination with an antisense oligonucleotide synergistically improves the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium in chronic myeloid leukemia cell lines.
Konstantinov SM; Georgieva MC; Topashka-Ancheva M; Eibl H; Berger MR
Mol Cancer Ther; 2002 Aug; 1(10):877-84. PubMed ID: 12492121
[TBL] [Abstract][Full Text] [Related]
36. Long-term culture of chronic myeloid leukemia (CML) bone marrow cells.
Santucci MA; Zaccaria A; Testoni N; Russo D; Zuffa E; Baccarani M; Tura S
Haematologica; 1991; 76(5):357-62. PubMed ID: 1806437
[TBL] [Abstract][Full Text] [Related]
37. 8-Cl-adenosine inhibits proliferation and causes apoptosis in B-lymphocytes via protein kinase A-dependent and independent effects: implications for treatment of Carney complex-associated tumors.
Robinson-White AJ; Bossis I; Hsiao HP; Nesterova M; Leitner WW; Stratakis CA
J Clin Endocrinol Metab; 2009 Oct; 94(10):4061-9. PubMed ID: 19773399
[TBL] [Abstract][Full Text] [Related]
38. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I
Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
[TBL] [Abstract][Full Text] [Related]
39. BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy.
Guo JQ; Lian JY; Xian YM; Lee MS; Deisseroth AB; Stass SA; Champlin RE; Talpaz M; Wang JY; Arlinghaus RB
Blood; 1994 Jun; 83(12):3629-37. PubMed ID: 8204887
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
Maki G; Tam YK; Berkahn L; Klingemann HG
Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
